Monoclonal antibodies as therapeutic agents for cancer

Lancet Oncology

Volumn 5, Issue 5, 2004, Pages 292-302

  Harris, Marion ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALICHEAMICIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DOCETAXEL; DOXORUBICIN; EDRECOLOMAB; EPRATUZUMAB; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; OREGOMOVAB; PACLITAXEL; PREDNISOLONE; RICIN; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ANEMIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; FEVER; GENETIC ENGINEERING; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LIVER TOXICITY; MANTLE CELL LYMPHOMA; METASTASIS; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RIGOR; SEPSIS; SIGNAL TRANSDUCTION; SMALL CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLINICAL TRIALS; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 2142714017     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(04)01467-6     Document Type: Review

References (81)

1. Stocchi L Nelson H. Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer Dis Colon Rectum 41 1998 232-250
2. Scott AM Renner C. Tumour antigens recognised by antibodies Encyclopaedia of life sciences 2001 1-7 Nature Publishing Group, Macmillan London
3. Kreitman R. Immunotoxins in cancer therapy Curr Opin Immunol 11 1999 570-578
4. Rayzman V Scott A. Monoclonal antibodies for cancer therapy Cancer Forum 26 2002 104-108
5. Hainsworth J. Monoclonal antibody therapy in lymphoid malignancies Oncologist 5 2000 376-384
6. McLaughlin P Grillo-Lopez J White C et al. IDEC-C2B8 rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825-2833
7. Davis T Grillo-Lopez A White C et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkins lymphoma: safety and efficacy of retreatment J Clin Oncol 18 2000 3135-3143
8. Czuczman M Grillo-Lopez A White C et al. Treatment of patients with low-grade B- cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 17 1999 268-276
9. Czuczman M, Grillo-Lopez A, LoBuglio A, et al. Patients with low-grade NHL treated with rituximab and CHOP experience prolonged clinical and molecular remission. Blood 2003;102: abstr 1493.
10. Marcus R, Imrie K, Belch A, et al. An international multi-centre, randomised, open-label phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular Non-Hodgkins lymphoma. Blood 2003; 102: abstr 87.
11. Coiffier B Ketterer N Haioun C et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicentre phase II study Blood 92 1998 1927-1932
12. Coiffier B Lepage E Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235-242
13. Coiffier B, Herbrecht R, Tilly H, et al. GELA study comparing CHOP and R-CHOP in elderly patients with DLCL: 3-year median follow-up with analysis according to co-morbidity factors. Proc Am Soc Clin Oncol 2003; 22: 596 (abstr).
14. Mounier N Briere J Gisselbrecht C et al. Rituximab and CHOP (R-CHOP) overcomes bcl2-associated resistance to chemotherapy in elderly patients with diffuse large B cell lymphoma (DLBCL) Blood 101 2003 4279-4284
15. Howard O Gribben J Neuberg D et al. Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival J Clin Oncol 20 2002 1288-1294
16. Magni M Di Nicola M Devizzi L et al. Successful in vivo purging of CD34- containing peripheral-blood harvests in mantle-cell and indolent lymphoma: evidence for a role for both chemotherapy and rituximab infusion Blood 96 2000 864-869
17. Brugger W, Hirsch J, Repp R, et al. Treatment of follicular and mantle-cell non-Hodgkin's lymphoma with anti-CD20 antibody rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral-blood stem-cell transplantation. Blood 2000; 96 (suppl) : 482 (abstr).
18. Almasri N Duque R Iturraspe J et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia Am J Hematol 40 1992 259-263
19. Byrd J Murphy T Howard R et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small-cell lymphocytic lymphoma demonstrated clinical activity and acceptable toxicity J Clin Oncol 19 2001 2153-2164
20. O'Brien S Kantarjian H Thomas D et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia J Clin Oncol 19 2001 2165-2170
21. Hainsworth J Litchy S Barton J et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small-cell lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network J Clin Oncol 21 2003 1746-1751
22. Byrd J, Petersen B, Park K, et al. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia patients: results from CALGB 9712. Blood 2001; 98: abstr 772.
23. Wierda W, O'Brien S, Albitar M, et al. Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98: abstr 771.
24. Dimopoulos M Zervas C Zomas A et al. Treatment of Waldenstrom's macroglobulinemia J Clin Oncol 20 2001 2326-2333
25. Zinzani P Ascani S Piccaluga P et al. Efficacy of rituximab in hairy-cell leukemia J Clin Oncol 15 2000 3875-3877
26. Milpied N, Vasseur B, Parquet N, et al. Humanised CD20 monoclonal antibody (rituximab) in post-transplant B lymphoproliferative disorder: a retrospective analysis on patients. Ann Oncol 2000; 11 (suppl) : 113.
27. Berney T Delis S Kato T et al. Successful treatment of post-transplantation lymphoproliferative disease with prolonged rituximab treatment in intestinal-transplant recipients Transplantation 74 2002 1000-1006
28. Hsi E, Hussein M, Elson P, et al. Biologic and clinical evaluation of rituxan in the management of newly diagnosed multiple myeloma patients: an update. Proc Am Soc Clin Oncol 2001; 21: 299 (abstr).
29. Conconi A, Thielblemont C, Martinelli G, et al. An international extranodal lymphoma study group phase II study of rituximab in extranodal marginal-zone B-cell lymphomas. Proc Am Soc Clin Oncol 2001; 21: 296 (abstr).
30. Ekstrand B, Lucas J, Horwitz, A et al. Rituximab in lymphocyte-predominant Hodgkins disease: results of a phase II trial. Proc Am Soc Clin Oncol 2002; 21: 264 (abstr).
31. Feuerstein M, Leonard J, Cooper N, et al. The use of rituximab in 28 adults with chronic immune thrombocytopenic purpura. Proc Am Soc Clin Oncol 2003; 2: 187 (abstr).
32. Ghazal H, Successful treatment of pure-red-cell aplasia with rituxan in patients with CLL. Blood 2001; 98: abstr 219.
33. Ahrens N Kingreen D Seltsam A et al. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab) Br J Haematol 114 2001 244-245
34. Kaplan L, Lee J, Scadden D. No benefit from rituximab in a randomised phase III trial of CHOP with or without rituximab for patients with HIV-associated Non-Hodgkin's lymphoma: updated data from the AIDS Malignancies Consortium study. Blood 2003; 102: abstr 1488.
35. Witzig T White C Wiseman G et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non- Hodgkins lymphoma J Clin Oncol 17 1999 3793-3803
36. Witzig T Flinn I Gordon L et al. Treatment with ibritumomab tiuexetan radioimmunotherapy in patients with rituximab-refractory follicular NHL J Clin Oncol 20 2002 3262-3269
37. Witzig T Gordon L Cabanillas F et al. Randomised control trial of Yttrium 90-labelled ibritumomab tiuexetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453-2463
38. Kaminski M Zelenetz A Press O et al. Pivotal study of iodine 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphomas J Clin Oncol 19 2001 3918-3928
39. 131 tositumomab produces a meaningful therapeutic benefit for patients with relapsed, refractory and transformed low-grade NHL: summary of the long-term response population. Proc Am Soc Clin Oncol 2003; 22: 576 (abstr).
40. Kaminski M, Estes J, Regan D, et al. Front-line treatment of advanced B-cell low- grade lymphoma with radiolabelled anti-B1 antibody: initial experience. Proc Am Soc Clin Oncol 1997; 16: 15 (abstr).
41. Dillman R. Radiolabelled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma J Clin Oncol 20 2002 3545-3557
42. Press O Unger J Braxial R et al. A phase II trial of CHOP followed by bexxar (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphoma (SWOG 9911) Blood 98 2001 843-844
43. Mass R, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000; 19: 75 (abstr).
44. Cobleigh M Vogel C Tripathy D et al. Multinational study of the efficacy and safety of humanised anti-HER 2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639-2648
45. Slamon D Leyland-Jones B Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783-792
46. Osaba D Slamon D Burchmore M et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer J Clin Oncol 20 2002 3106-3113
47. Vogel C, Cobleigh M, Tripathy D, et al. First-line herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61 (suppl) : 37-42.
48. Esteva F Valero V Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 1800-1808
49. Burnstein H Kuter I Campos S et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 19 2001 2722-2730
50. Leyland-Jones B Gelmon K Ayab J et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel J Clin Oncol 21 2003 3965-3971
51. Seidman A Hudis C Pierri M et al. Cardiac dysfunction in the trastuzumab clinical-trial experience J Clin Oncol 20 2002 1215-1221
52. Chee K, Lara N, Longmate J, et al. Trastuzumab and docetaxel in HER2+ hormone-refractory prostate cancer: a California Cancer Consortium screening and phase II trial. Proc Am Soc Clin Oncol 2003; 22: 403 (abstr).
53. Gatzemeier U Groth G Butts C et al. Randomised phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann Oncol 15 2004 19-27
54. Bookman M Darcy K Clarke-Pearson D et al. Evaluation of monoclonal humanised anti-HER2 antibody, trastuzumab in patients with recurrent or refractory ovarian or peritoneal cancer with overexpression of HER2: a phase II trial of the Gynaecologic Oncology Group J Clin Oncol 21 2003 283-290
55. Griffin J Linch D Sabbath K et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk Res 8 1984 521-534
56. Schedinberg D Lovett D Divgi C et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone-marrow targeting and internalisation of radionuclide J Clin Oncol 9 1991 478-490
57. Sievers E Larson R Stadtmauer E et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 19 2001 3244-3254
58. Keating M Flinn I Jain V et al. Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: results of a large international study Blood 99 2002 3554-3561
59. Lundin J Kimby E Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia Blood 100 2002 768-773
60. Kennedy S, Rawston A, Svans P, et al. Campath-H1 therapy in 29 patients with refractory CLL: true complete remission is an attainable goal. Blood 1999; 94: abstr 603.
61. Perez S Kottaridis P Martino R et al. Non-myeloablative transplantation with or without alemtuzumab: comparison between two prospective studies in patients with lymphoproliferative disorders Blood 100 2002 3121-3127
62. Keating M Cazin B Coutre S et al. Campath H1 treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen had failed J Clin Oncol 20 2002 205-213
63. Kim E Khuri F Herbst R. Epidermal growth-factor receptor biology (IMC-C225) Curr Opin Oncol 13 2001 506-513
64. Mendelsohn J. The epidermal growth factor as a target for cancer therapy Endo Rel Cancer 8 2001 3-9
65. Cunningham D, Humblet Y, Sienas S, et al. Cetuximab (c225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth-factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22: 252 (abstr).
66. Robert F Esekiel M Spencer S et al. Phase I study of anti-epidermal growth-factor receptor cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 3234-3243
67. Baselga J, Trigo J, Bouthis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients with recurrent/metastatic squamous-cell carcinoma of the head and neck progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002; 21: 226 (abstr).
68. Abbruzzese J, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth- factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: 30 (abstr).
69. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab in combination with cisplatin/vinorelbine vs cisplatin/vinorelbine alone in the first-line treatment of patients with epidermal growth-factor receptor-expressing advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 642 (abstr).
70. Kim E, Mauer A, Tran H, et al. A phase II study of cetuximab, an epidermal growth-factor receptor blocking antibody in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 642 (abstr).
71. Saltz L, Kies M, Abbruzzese J, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22: 204 (abstr).
72. Kleinsmith L, Kerrigan D, Kelly J. National Cancer Institute: Science behind the news. Understanding angiogenesis. http://press2.nci.nih.gov/sciencebehind/angiogenesis/angio01.htm (accessed April, 2004).
73. Rosen L. Clinical experience with angiogenesis-signalling inhibitors: focus on vascular-endothelial growth-factor (VEGF) blockers Cancer Control 9 suppl 2 2002 36-44
74. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22: abstr 3646.
75. Yang J Haworth L Sherry R. A randomised trial of bevacizumab, an anti-vascular-endothelial growth-factor antibody for metastatic renal cancer N Engl J Med 349 2003 427-434
76. DeVore R, Fehrenbacher L, Herbst R, et al. A randomised phase II trial comparing rhumab (recombinant humanised monoclonal antibody to vascular-endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage 3B/4 NSCLC. Proc Am Soc Clin Oncol 2000; 19: 485 (abstr).
77. Novotny W, Holmgren E, Griffing S, et al. Identification of squamous histology and central, cavitary tumours as possible risk factors for pulmonary (PH) haemorrhage in patients with advanced NSCLC receiving bevacizumab. Proc Am Soc Clin Oncol 2001; 20: 330 (abstr).
78. Miller K, Rugo H, Cobleigh M, et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treated with anthracycline and a taxane. Breast Cancer Res Treat 2002; 76 (suppl): abstr 36
79. Riethmuller G Holz E Schlimok G et al. Monoclonal antibody for resected Dukes C colorectal cancer: seven-year outcome of a multicentre randomised trial J Clin Oncol 16 1998 1788-1794
80. Punt C Nagy A Douillard J et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study Lancet 360 2002 671-677
81. Ehlen T, Gordon A, Fingert H, et al. Adjuvant treatment with monoclonal antibody ovarex MAb-B43·13 (OV) targeting CA125 induces robust immune responses associated with prolonged time-to-relapse in a in a randomised placebo-controlled study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 2002; 21: 9 (abstr).